STOCK TITAN

Director Jesper Hoeiland joins Allarity Therapeutics (ALLR) with initial Form 3 filing

(Neutral)
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Allarity Therapeutics filed an initial ownership report for director Jesper Hoeiland. This Form 3 identifies Hoeiland as a director of Allarity Therapeutics, Inc. and serves as his initial statement of beneficial ownership in the company’s securities. The filing does not list any reportable transactions or derivative positions at this time.

Positive

  • None.

Negative

  • None.
Form 3 regulatory
"This Form 3 identifies Hoeiland as a director of Allarity Therapeutics, Inc."
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
beneficial ownership financial
"serves as his initial statement of beneficial ownership in the company’s securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
reporting person regulatory
"It formally records his status as a reporting person under SEC rules"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does the Allarity Therapeutics (ALLR) Form 3 for Jesper Hoeiland show?

The Form 3 identifies Jesper Hoeiland as a director of Allarity Therapeutics, Inc. It serves as his initial statement of beneficial ownership, with no specific transactions or holdings detailed in the summarized data.

Does the ALLR Form 3 report any stock purchases or sales by Jesper Hoeiland?

The summarized Form 3 data shows no reported transactions by Jesper Hoeiland. Buy, sell, exercise, gift, tax withholding, and restructuring counts are all listed as zero in the transaction summary.

Are any derivative securities reported for Jesper Hoeiland in Allarity Therapeutics’ Form 3?

The derivative section for Jesper Hoeiland is empty in this Form 3 snapshot. The derivativeSummary shows no options or other derivative positions reported as of this filing’s disclosure.

What is the purpose of this Allarity Therapeutics (ALLR) Form 3 filing?

This Form 3 functions as an initial beneficial ownership statement for director Jesper Hoeiland. It formally records his status as a reporting person under SEC rules, even though no specific holdings or transactions are listed here.

Does the ALLR Form 3 indicate Jesper Hoeiland is a 10% owner of Allarity Therapeutics?

The Form 3 data flags Jesper Hoeiland as a director but not as a 10% owner. The is_ten_percent_owner field is set to zero, indicating he is not reported as owning 10% or more of the company’s stock.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Hoeiland Jesper

(Last)(First)(Middle)
C/O ALLARITY THERAPEUTICS, INC.
123 E TARPON AVE

(Street)
TARPON SPRINGS FLORIDA 34689

(City)(State)(Zip)

UNITED STATES

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
06/10/2025
3. Issuer Name and Ticker or Trading Symbol
Allarity Therapeutics, Inc. [ ALLR ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
No securities are beneficially owned.
/s/ Jesper Hoeiland05/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)